血液ACE蛋白水平偏低或提示治疗抵抗性精神病
Low levels of blood pressure protein may flag treatment-resistant psychosis
一项纳入200人的初步研究显示,治疗抵抗性精神病患者血液中ACE蛋白水平显著低于非治疗抵抗者,且血液与脑脊液ACE水平相关,提示血液检测或能反映脑内情况。研究团队认为ACE蛋白在精神病中或有未知功能,尚需更大样本验证。
初步研究发现治疗抵抗性精神病患者血液ACE蛋白水平偏低,提示该蛋白或超出血压调节、参与精神病机制,为客观识别这类患者提供了新方向。
In a preliminary study using blood and spinal fluid samples from 200 people, Johns Hopkins Medicine researchers say they have evidence that a well-studied protein involved in blood pressure regulation may serve as a marker for—and perhaps play a role in—treatment-resistant schizophrenia and other psychoses.
The findings, if confirmed in larger studies, could eventually contribute to more objective ways of identifying people with psychosis who may need different treatment approaches, the researchers say.
ACE may have an unrecognized role
In the study published online Sept. 9 in JAMA Psychiatry, researchers found significantly lower levels of angiotensin-converting enzyme (ACE), a protein that helps regulate blood pressure, in the blood of people with treatment-resistant psychosis compared with people with early-stage psychosis not classified as treatment-resistant. Importantly, the investigators say, ACE protein levels in blood correlated with ACE levels in cerebrospinal fluid, suggesting that a simple blood test may accurately reflect what is happening in the brain.
Because ACE is known to narrow blood vessels, ACE inhibitors are widely prescribed for hypertension, blocking the protein from doing its normal job. "The new findings suggest this protein may be doing something entirely different in the context of psychosis," says Akira Sawa, M.D., director of the Johns Hopkins Schizophrenia Center.
"Our next step is to understand this additional, unrecognized function of ACE protein. If we can establish this relationship in larger and independent studies, ACE could potentially become part of a broader panel of biological markers that helps us better understand and ultimately treat psychotic disorders."
Sawa notes that previous studies identified higher-than-normal levels of ACE as a genetic risk for schizophrenia, although what the gene that codes for the protein actually does has been unclear.
"This study provides some evidence that genetic alterations in the gene for ACE affect the level of the protein it makes, which in turn may influence the biology of psychosis, particularly in patients whose symptoms do not respond adequately to standard treatments," says Kun Yang, Ph.D., an assistant professor of psychiatry and behavioral sciences at Johns Hopkins Medicine.
Seeking biological signs of treatment resistance
Psychotic disorders, including schizophrenia, are currently diagnosed primarily through evaluation and assessment of symptoms and behaviors, including hallucinations, delusions and disordered thinking. Sawa says there are currently no objective biological blood or other tests that can determine which people with psychoses are likely to develop treatment resistance. Identifying biological differences associated with treatment resistance could help researchers develop more precise approaches to diagnosis and treatment, including the identification of new drug targets.
For the study, researchers analyzed data from 200 participants, including 78 healthy controls and 122 people with early-stage psychosis. Among the participants with psychosis, 31 had treatment-resistant psychosis and 91 did not. The researchers measured ACE protein levels in blood and cerebrospinal fluid, examined ACE enzymatic activity and analyzed genetic data related to schizophrenia risk. They found that ACE protein levels were significantly lower in both cerebrospinal fluid and blood among people with early-stage psychosis compared with healthy controls.
The researchers also found that participants with treatment-resistant psychosis had lower levels of ACE protein in their blood than patients who were not treatment-resistant, but they found no significant difference in the protein's enzyme activity between the two groups.
Beyond blood pressure regulation
The contrast between ACE protein levels and its enzymatic activity suggests that ACE may play a role in psychosis through biological functions unrelated to its role in regulating blood pressure through the renin-angiotensin system.
The researchers say their findings may also have applications beyond psychiatry. In recent years, scientists have discovered that some proteins "moonlight"—performing hidden functions unrelated to their established roles.
A notable example is glyceraldehyde-3-phosphate dehydrogenase (GAPDH), whose moonlighting function was discovered by Johns Hopkins Medicine researchers. Long known solely for its essential role in breaking down glucose for energy, GAPDH is now recognized to influence cell death. It's possible, they say, that ACE may be another such moonlighting protein, a discovery that could spark new lines of research in neuroscience and molecular biology.
Publication details
Kun Yang et al., Angiotensin-Converting Enzyme in Patients With Early-Stage Psychosis, JAMA Psychiatry (2026). DOI: 10.1001/jamapsychiatry.2026.2588
Journal information: JAMA Psychiatry
Clinical categories
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Low levels of blood pressure protein may flag treatment-resistant psychosis (2026, October 12) retrieved 12 October 2026 from https://medicalxpress.com/news/2026-10-blood-pressure-protein-flag-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com